Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.42 |
| ▸ | HRH1 | P35367 | 3/20 | 0.39 |
| ▸ | IKBKB | O14920 | 3/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.33 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775269 | 0.92 | CHRNB2 (0.43) | IRAK4ROCK1CHUKROCK2PRKCZ | |
| SCHEMBL29003898 | 0.80 | IRAK4 (0.49) | IRAK4ROCK1HRH1IKBKBSYK | |
| SCHEMBL30422551 | 0.80 | IRAK4 (0.49) | IRAK4ROCK1HRH1IKBKBSYK | |
| SCHEMBL30775199 | 0.79 | IRAK4 (0.44) | IRAK4ROCK1CHUKROCK2PRKCZ | |
| SCHEMBL13920500 | 0.78 | IRAK4 (0.50) | IRAK4ROCK1HRH1IKBKBSYK | |
| SCHEMBL29003863 | 0.77 | IRAK4 (0.49) | IRAK4ROCK1HRH1IKBKBSYK | |
| SCHEMBL30422003 | 0.77 | IRAK4 (0.49) | IRAK4ROCK1HRH1IKBKBSYK | |
| SCHEMBL940757 | 0.73 | SYK (0.51) | IRAK4ROCK1HRH1IKBKBSYK | |
| SCHEMBL759186 | 0.73 | HRH1 (0.52) | IRAK4ROCK1HRH1IKBKBSYK | |
| Hydrochloric Acid SCHEMBL2447452 | 0.72 | HRH1 (0.50) | IRAK4ROCK1HRH1IKBKBSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414048-B2 | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| EP-1119568-B1 | 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | JANSSEN PHARMACEUTICA NV (BE) | 2004-02-18 | — | — | EP | disclosed |
| US-20040019059-A1 | 4,5-Dihydro-isoxazole derivatives and their pharmaceutical use | FREYNE EDDY JEAN EDGARD (BE) | 2004-01-29 | — | — | US | disclosed |
| US-6583141-B1 | T cell mediated rheumatic diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-24 | — | — | US | disclosed |
| EP-1119568-A1 | 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021959-A1 | 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019059-A1 | 4,5-Dihydro-isoxazole derivatives and their pharmaceutical use | CBR1, CYP2D6, HSD3B1 | IRAK4 2675/4885ROCK1 1958/4885HRH1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.